胃癌中EZH2的表达及临床评估

Enhancer of Zeste Homolog 2(EZH2) Expression in Gastric Cancer and its Clinical Evaluation

目的:探讨EZH2在胃癌中的表达及其临床意义。方法:采用逆转录荧光PCR方法检测胃癌组织和配对的正常组织中EZH2的表达,分析EZH2与临床病理参数之间的关系。结果:53例标本中34例(64.15%,34/53)癌组织中EZH2表达增高,EZH2在胃癌组织中的表达明显高于配对正常组织(P<0.05)。EZH2表达在低分化胃癌中表达明显高于高-中分化胃癌(P<0.01);EZH2表达在T3-T4期表达增高,明显高于T1-T2期(P<0.05);而EZH2的表达与性别、年龄等因素无关。结论:EZH2在胃癌组织表达增高,与分化程度及TNM分期有关,提供胃癌的进展和肿瘤形成;并预测胃癌治疗的预后方面,可能是一种新的生物标志物。

Objective To probe the clinical significance of EZH2 expression in gastric cancer.Methods The EZH2 mRNA expression was detected in the gastric cancer tissues and the matched normal tissues by reverse transcriptional real time PCR,and the relationship between EZH2 expression and clinical pathological characteristic was analyzed.Results Among 53 samples,the expression of EZH2 was significantly increased in 34 gastric cancer tissues（64.15%,34/53）,compared with the matched normal tissues（P0.05）.The level of EZH2 in the poorly differentiated gastric cancer was higher evidently than the well-differentiated（P0.01）.The T3-T4 stage gastric cancer expressed more EZH2 than T1-T2 stage（P0.05）.There was no correlation between EZH2 and ages or sex.Conclusion EZH2 is overexpressed in gastric cancer,and EZH2 may contribute to the progression and oncogenesis of human gastric cancers,suggesting that EZH2 might be a new biomarker for predicting the prognosis or therapy of gastric cancers.